OP NanoPharma Co., Ltd. Yunlin Plant

OP NanoPharma is a joint investment of Orient EuroPharma and NanoCarrier Co., Ltd., in Japan and mainly develops oncology drugs including Micelplatin, Nanopaclitaxel and YQ1 for head and neck, breast cancer, ovarian cancer and non-small cell lung cancer and other cancers. Source (opens in a new tab)

Website

https://www.oepgroup.com/

Headquarters

TW

Provider types

CDMO